Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Radiation Pneumonitis 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

pegaspargase 4Oxaliplatin 3Gemcitabine 3Methotrexate 2Etoposide 2Early Intervention, Educational 2Doxorubicin 2Dexamethasone 2sugemalimab 1ferrous sulfate 1ferric gluconate 1Vincristine 1Thalidomide 1Sucrose 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Psychiatric Rehabilitation 1Prednisone 1Pharmacogenomic Testing 1Ketamine 1Drug Therapy 1Darbepoetin alfa 1Cyclophosphamide 1Ciprofloxacin 1Asian ginseng 1Amoxicillin-Potassium Clavulanate Combination 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Extranodal NK-T-Cell × sugemalimab × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡